ATS View
한국어

Cellbion KRX:308430KOSDAQ

셀비온 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h1
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11

In Q2 2026, Cellbion reported revenue of ₩472m, up 16.7% year on year, and an operating loss of ₩2.6bn. Cellbion (셀비온) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 4 articles. The most common catalyst was tech & capacity (3).

Cellbion quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩472m+16.7%−₩2.6bn₩14.4bn
Q1 2026₩613m+27.7%−₩2.4bn−₩2.4bn
Q4 2025 derived₩382m-32.6%−₩2.5bn−₩2.4bn
Q3 2025₩679m-42.3%−₩2.0bn−₩1.8bn
Q2 2025₩404m+17.6%−₩2.1bn−₩1.9bn
Q1 2025₩480m+138.3%−₩1.7bn−₩1.4bn
Q4 2024 derived₩567m+23.2%−₩2.2bn−₩2.4bn
Q3 2024₩1.2bn+277.5%−₩1.7bn−₩1.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Cellbion top stories 2 weeks, by number of outlets

  1. 1
    셀비온, AI 기반 방사성의약품 플랫폼 국책과제 선정
    2 outlets · 2 articlesFirst report Sep 14 08:08 히트뉴스Policy
  2. 2
    셀비온, 산업부 ‘AI 기반 PRC 개발’ 국책과제 선정…차세대 RPT 정조준
    1 outlets · 1 articlesFirst report Sep 14 15:29 이데일리Policy
  3. 3
    셀비온, 바이오헬스분야 연구개발사업 신규 지원 대상과제 선정
    1 outlets · 1 articlesFirst report Sep 14 10:28 서울경제

Latest Cellbion news Korean headlines